​Exclusive to T2B Pro and Student members.

​​If you're not part of Ticket to Biotech, confirm you're eligible, and join as a Pro or Student member before registering for this event:

​​T2B Intake Form

​​***If you do not receive your event confirmation within 1 business day of RSVPing (above), check your email spam folder. The automated Luma email includes the Zoom info and cal invite.***

​ONE SIZE DOESN'T FIT ALL: IR ACROSS MARKET CAPS

​Not all IR functions look the same, but the stakes are consistently high. Like strategic communications, the goals, strategies, and scale of IR programs depend on a company’s market cap, development stage, and geographic reach. Recognizing these differences is critical when aligning IR with broader communications and corporate affairs priorities.

​In this one-hour virtual panel, hear from deeply experienced IR leaders representing the small-cap, mid-cap, and large-cap perspectives. Speakers Susie Lisa of Vertex and Jen Harsey Robinson, most recently at Verve, both blend Wall Street and in-house expertise to lead companies through significant value-creating milestones and everything in between.

​Why Attend:

• ​Gain perspective on how IR priorities shift across market caps and stages

• ​Explore where IR and communications intersect, and how to navigate shared ownership of critical moments

• ​Hear how senior IR leaders approach milestone communications and ongoing market engagement, and what that means for communicators partnering with them

​Featuring:

• ​Susie Lisa, Senior Vice President, Investor Relations, Vertex Pharmaceuticals

• ​Jennifer Harsey Robinson, most recently Senior Vice President, Investor Relations and Corporate Communications, Verve Therapeutics (acquired by Lilly)

​Panel moderator:

• ​David Connolly, T2B IR Roundtable Member and Head of Investor Relations and Corporate Communications, Rhythm Pharmaceuticals 

​

​MEET OUR GUEST SPEAKERS

​SUSIE LISA

​Senior Vice President, Investor Relations, Vertex Pharmaceuticals

​Susie Lisa is Senior Vice President, Investor Relations, for Vertex Pharmaceuticals, having joined in September 2022. Previously, she worked for more than a decade in investor relations for leading health care companies in the New England region, including Boston Scientific, CVS Health, and Abiomed. Under her leadership, the Vertex IR program and IR team were ranked #1 overall in Biotechnology by Institutional Investor for the past two years. At Boston Scientific, the IR team was also ranked #1 overall by Institutional Investor in its sector, including best Investor Relations program and best communication of strategy and risk management amid COVID-19. In 2019, Susie was named by IR Magazine as Best Investor Relations Officer (large cap, across all sectors).

​Prior to her investor relations experience, Susie spent over twenty years in a variety of Wall Street-related roles, including 12 years at Bank of America Merrill Lynch, where she was a Managing Director and Head of Americas Specialist Sales with a focus in healthcare equity research sales. She also has worked at Cowen & Co. and JPMorgan Chase as an equity research analyst in the medical device sector, in healthcare investment banking, and in convertible bond sales. She earned a BA in Economics and Political Science from Duke University and an MBA in Finance from New York University – Stern School of Business and is a CFA charter holder.

​Susie and her husband, Tony, live in Boston, Massachusetts and have three children (all in college or graduate school) and two Labrador retrievers.

​

​JENNIFER HARSEY ROBINSON

​Formerly Senior Vice President, Investor Relations and Corporate Communications, Verve Therapeutics

​Jen Harsey Robinson most recently served as Senior Vice President of Investor Relations and Corporate Communications at Verve Therapeutics, joining in November 2021 until the company’s completed acquisition by Lilly in July 2025. She brings more than 20 years of biopharmaceutical industry experience spanning investor relations, corporate communications and the buyside. Prior to Verve, she held senior leadership roles overseeing investor relations and corporate communications at Deciphera Pharmaceuticals, resTORbio, Ra Pharmaceuticals, ARIAD Pharmaceuticals and Dyax. Earlier in her career, she worked in investment research and analysis roles at Putnam Investments, RiverSource Investments, and Leerink Swann. Jen earned her BA from Dartmouth College.

​

​DAVID CONNOLLY

​VP, IR and Corporate Communications, Rhythm Pharmaceuticals

​David Connolly is a seasoned leader in healthcare and biotech investor relations and corporate communications. With a diverse background spanning various disease areas and both public and private companies, Connolly has consistently contributed to strategic roles with a focus on collaboration and effective communication.

​As Vice President of Investor Relations and Corporate Communications at Rhythm Pharmaceuticals, Connolly leads development of company messaging, investor engagement and corporate disclosures. Since joining Rhythm initially as senior director in 2019, he has led communications efforts for four Phase 3 clinical trials, three FDA approvals and multiple business development deals. Since joining Rhythm, the Company has raised more than $1B from multiple financings. 

​Prior to joining Rhythm, Connolly served as Vice President of IR and Corporate Communications at Ziopharm Oncology. His career also includes senior roles at JPA Health Communications and LaVoie Strategic Communications. In these positions, he directed integrated communications programs for biotech and biopharma clients, overseeing major collaborations and multimedia content development. Earlier in his career, Connolly held leadership positions in communications and marketing at Boston area hospitals, including Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center. He began his career as a journalist at daily newspapers outside Boston and taught high school Latin, roles that provided a strong foundation in strategic communications. Connolly graduated from Holy Cross College with a bachelor’s degree in classics.